Component Page

Home

Laboratory Services

Our Tests

Contact Us

Lanka Hospitals quick link Lanka Hospitals quick link

Sustainability

Founded in 1945, the Mahindra Group is one of the largest and most admired multinational federation of companies with 260,000 employees in over 100 countries. It enjoys a leadership position in farm equipment, utility vehicles, information technology and financial services in India and is the world’s largest tractor company by volume. It has a strong presence in renewable energy, agriculture, logistics, hospitality and real estate.information technology and financial services in India and is the world’s largest tractor company by volume. It ha

Selected by Mahindra

Selected by Mahindra & Mahindra Limited India, one of India’s leading automotive manufacturers with a growing global presence, Ideal Motors (Pvt) Limited revitalised the Mahindra brand in Sri Lanka, currently selling over seven thousand vehicles and working through a network of five fully fledged showrooms, a 32 strong dealer network and well equipped workshop.
The high growth and turnover performance has prompted M&M Limited to add other franchises into the product portfolio in Sri Lanka,
which ranges from two wheelers to heavy vehicles. The Chairman and Board of Directors of Ideal Motors (Pvt) Limited collate impressive knowledge levels and expertise in the business and motor industry, with award winning sporting tenets and leadership infusions through the Deputy Chairman fueling the ideal combination for a successful business.
Explore More
What does your company specialize in?
We understand that buying or selling a property is one of the biggest financial transactions a person makes, and at Gangani Land Sales we aim to take the stress out of the equation and deliver results over and above the customer expectations. We consistently utilize the best land management professionals to improve our service which in turn delivers great results to the customers. During the sales and purchasing process you will be fully involved in all decisions and kept informed of all facet of the process from beginning to the end of the steps.
What does your company specialize in?
We understand that buying or selling a property is one of the biggest financial transactions a person makes, and at Gangani Land Sales we aim to take the stress out of the equation and deliver results over and above the customer expectations. We consistently utilize the best land management professionals to improve our service which in turn delivers great results to the customers. During the sales and purchasing process you will be fully involved in all decisions and kept informed of all facet of the process from beginning to the end of the steps.
What does your company specialize in?
We understand that buying or selling a property is one of the biggest financial transactions a person makes, and at Gangani Land Sales we aim to take the stress out of the equation and deliver results over and above the customer expectations. We consistently utilize the best land management professionals to improve our service which in turn delivers great results to the customers. During the sales and purchasing process you will be fully involved in all decisions and kept informed of all facet of the process from beginning to the end of the steps.
What does your company specialize in?
We understand that buying or selling a property is one of the biggest financial transactions a person makes, and at Gangani Land Sales we aim to take the stress out of the equation and deliver results over and above the customer expectations. We consistently utilize the best land management professionals to improve our service which in turn delivers great results to the customers. During the sales and purchasing process you will be fully involved in all decisions and kept informed of all facet of the process from beginning to the end of the steps.

Chairman’s Review: Financial Year 2023/24 First Nine Months Performance

Explore

Chairman’s Review: Financial Year 2023/24 First Nine Months Performance

Explore

Component Page

Component Page

Leading With Innovation

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Lorem Ipsum passage

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Lorem Ipsum passage

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Lorem Ipsum passage

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.






By ticking the checkbox, you voluntarily and explicitly consent to The Lanka Hospitals Corporation PLC and/or its subsidiary, Lanka Hospitals Diagnostics (Private) Limited collecting, storing and processing (manually and/or by automated means) your personal data, including your name, email address, contact details, location and browsing activity, in accordance with the data protection laws, for the purposes of providing healthcare services, appointment scheduling, medical consultations, and other related hospital and laboratory services.
As the data subject, you have the right to access, rectify, erase and object to data processing. Further, your consent can be withdrawn at any time upon written request to [email protected] . without having to give any reason. This shall not affect the lawfulness of data processing based on consent before its withdrawal. If consent is not withdrawn, it is valid until it is withdrawn. Upon withdrawal or assertion of your right to erasure, we will delete your personal data unless legally required to retain it. Refusing or withdrawing consent will not result in any disadvantages.



Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
All
Common Tests
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
PCR – KRAS Mutation Detection
Other Names: RD1307
Methods:  Conventional PCR followed by Sanger Sequencing
TAT: 21 Days
Dept: Mol.B
Specimen 01: Tissue
Container 01: Paraffin Block
Description: Detection of KRAS codons 12,13 & 61 mutations in colorectal and non-small-cell lung cancers, Useful in predicting individual’s response to cetuximab and panitumumab treatment of metastatic colorectal cancer.
PCR – M. tuberculosis (TB)
Other Names: 2434
Methods:  SYBR Green based Real Time PCR followed by melting curve analysis
TAT: 07 Days
Dept: Mol.B
Specimen 01: Whole Blood
Container 01: EDTA
Specimen 02: Whole Blood
Container 02: EDTA
Specimen 03: Sputum/BAL/Bronchial secretions
Container 03: USC
Specimen 04: Urine/CSF/Tissue/Acetic Fluid/Pleural Fluid
Container 04: USC
Description: Diagnosis of tuberculosis caused by Mycobacterium tuberculosis
PCR – MDR-TB Genotyping
Other Names: 9950
Methods:  Outsourcse
TAT: 10 Days
Dept: Mol.B
Specimen 01: Any biological specimen
Container 01: USC
Specimen 02: Any biological specimen
Container 02: USC
Description: Diagnosis of tuberculosis caused by Mycobacterium tuberculosis
PCR – Neisseria gonorrhoeae
Other Names: 9801
Methods: SYBR Green based Real Time PCR followed by melting curve analysis
TAT: 07 Days
Dept: Mol.B
Specimen 01: Urine
Container 01: USC
Specimen 02: Urine
Container 02: USC
Specimen 03: Urethral Swab
Container 03: Sterile Swab
Description: Diagnosis of Gonorrhoea.
PCR – NPM1 Mutation Detection
Other Names: 7579
Methods:  Conventional PCR followed by Sanger Sequencing
TAT: 21 Days
Dept: Mol.B
Specimen 01: Whole Blood
Container 01: EDTA
Description: Detection of NPM1 Exon 12 Mutations in patients suspected for Acute Myelogenous Leukemia (AML).
PCR – Parvovirus B19 DNA
Other Names: 3305
Methods:  SYBR Green based Real Time PCR followed by melting curve analysis
TAT: 07 Days
Dept: Mol.B
Specimen 01: Whole Blood
Container 01: EDTA
Specimen 02: Whole Blood
Container 02: EDTA
Description: Detection (qualitative) of Parvovirus which causes rashes on Face, Trunk & Limbs of children.
PCR – PML-RARA T(15:17) Detection
Other Names: 9905
Methods:   Conventional PCR followed by Agarose gel electrophoresis
TAT: 02 Days
Dept: Mol.B
Specimen 01: Whole Blood
Container 01: EDTA
Specimen 02: Whole Blood
Container 02: EDTA
Description: Detect the PML-RARA fusion, t(15;17), useful for diagnosis and monitoring of Acute Promyelocytic Leukemia (AML M3).
PCR – Salmonella,Shigella & Campylobacter In Stool
Other Names: 9416ST
Methods: Differential Cultures/ Biochemical reactions & Disk Diffusion Method for ABST
TAT: 02 Days
Dept: Mol.B
Specimen 01: Stool
Container 01: USC
Description: Detection of Salmonella,Shigella & Campylobacter in patients with diarrhea.
PCR – Toxoplasma gondii
Other Names: 7522
Methods:  SYBR Green based Real Time PCR followed by melting curve analysis
TAT: 04 Days
Dept: Mol.B
Specimen 01: Whole Blood
Container 01: EDTA
Description: Detection (Qualitative) Toxoplasmosis - useful in identifing T. gondii in clinical specimens of immunosuppressed patients.
1 78 79 80 81 82 97